Bone Marrow Transplantation - Table of Contents alert Volume 50 Issue 3

TABLE OF CONTENTS Volume 50, Issue 3 (March 2015) In this issue Editorial Reviews Original Articles Letters To The Editor EDITORIAL Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee C Chabannon, M Hildebrandt, S Scheding, A Humpe, M Lowdell and I Slaper-Cortenbach Bone Marrow Transplant 2015 50: 321-323; advance online publication, December 15, 2014; 10.1038/bmt.2014.271 Full Text REVIEWS Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases Y Ofran, H M Lazarus, A P Rapoport and J M Rowe Bone Marrow Transplant 2015 50: 324-333; advance online publication, January 12, 2015; 10.1038/bmt.2014.270 Abstract | Full Text A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies B E Shaw, D L Confer, W Hwang and M A Pulsipher Bone Marrow Transplant 2015 50: 334-340; advance online publication, January 19, 2015; 10.1038/bmt.2014.278 Abstract | Full Text ORIGINAL ARTICLES ACUTE LEUKEMIA High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT M Hengeveld, S Suciu, Y Chelgoum, J-P Marie, P Muus, F Lefrère, F Mandelli, F Pane, S Amadori, G Fioritoni, B Labar, F Baron, J Cermak, J-H Bourhis, G Storti, P Fazi, A Hagemeijer, M Vignetti, R Willemze and T de Witte Bone Marrow Transplant 2015 50: 341-347; advance online publication, November 17, 2014; 10.1038/bmt.2014.262 Abstract | Full Text Presence of CD34+CD38−CD58− leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT Y Kong, L-P Xu, Y-R Liu, Y-Z Qin, Y-Q Sun, Y Wang, H Jiang, Q Jiang, H Chen, Y-J Chang and X-J Huang Bone Marrow Transplant 2015 50: 348-353; advance online publication, December 8, 2014; 10.1038/bmt.2014.274 Abstract | Full Text Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL M Kim, J Park, D-W Kim, Y-J Kim, Y-W Jeon, J-H Yoon, S-H Shin, S-A Yahng, S-E Lee, B-S Cho, K-S Eom, H-J Kim, C-Ki Min, S-G Cho, Y Kim, J-W Lee, K Han, W-S Min and S Lee Bone Marrow Transplant 2015 50: 354-362; advance online publication, December 15, 2014; 10.1038/bmt.2014.281 Abstract | Full Text Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL J Harvey, A Green, S J Groves, J Cornish, J Moppett, M Cummins, L Keen, S Culliford, A Poles, W Hulme, Y Li and C G Steward Bone Marrow Transplant 2015 50: 363-366; advance online publication, January 12, 2015; 10.1038/bmt.2014.282 Abstract | Full Text LYMPHOMA Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders S Hong, J Le-Rademacher, A Artz, P L McCarthy, B R Logan and M C Pasquini Bone Marrow Transplant 2015 50: 367-374; advance online publication, December 1, 2014; 10.1038/bmt.2014.269 Abstract | Full Text PLASMA CELL DISORDERS CyBorD induction therapy in clinical practice N Areethamsirikul, E Masih-Khan, C-M Chu, V Jimenez-Zepeda, D E Reece, S Trudel, V Kukreti, R Tiedemann and C Chen Bone Marrow Transplant 2015 50: 375-379; advance online publication, January 19, 2015; 10.1038/bmt.2014.288 Abstract | Full Text AUTOIMMUNE DISORDERS Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients L C M Arruda, J C C Lorenzi, A P A Sousa, D L Zanette, P V B Palma, R A Panepucci, D S Brum, A A Barreira, D T Covas, B P Simões, W A Silva, Jr, M C Oliveira and K C R Malmegrim Bone Marrow Transplant 2015 50: 380-389; advance online publication, December 8, 2014; 10.1038/bmt.2014.277 Abstract | Full Text GRAFT MANIPULATION Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR G Blank, C Welker, J Haarer, M Sterk, S Nadalin, V A C Yañez, T O Joos, A Menrad, D Snell, G LaCorcia, A Königsrainer, R Handgretinger and K Schilbach Bone Marrow Transplant 2015 50: 390-401; advance online publication, November 17, 2014; 10.1038/bmt.2014.263 Abstract | Full Text CONDITIONING Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes M Gleimer, Y Li, L Chang, S Paczesny, D A Hanauer, D G Frame, C A Byersdorfer, P R Reddy, T M Braun and S W Choi Bone Marrow Transplant 2015 50: 402-410; advance online publication, December 22, 2014; 10.1038/bmt.2014.280 Abstract | Full Text HISTOCOMPATIBILITY AND DONOR SELECTION ISSUES Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT? A Hamdi, K Cao, L M Poon, F Aung, S Kornblau, M A Fernandez Vina, R E Champlin and S O Ciurea Bone Marrow Transplant 2015 50: 411-413; advance online publication, January 26, 2015; 10.1038/bmt.2014.285 Abstract | Full Text TRANSPLANT TOXICITIES Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children M Pillon, N S Carucci, C Mainardi, E Carraro, M Zuliani, L Chemello, E Calore, M Tumino, S Varotto, T Toffolutti, R Destro, M V Gazzola, R Alaggio, G Basso and C Messina Bone Marrow Transplant 2015 50: 414-419; advance online publication, January 12, 2015; 10.1038/bmt.2014.276 Abstract | Full Text Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage N K Rathi, A R Tanner, A Dinh, W Dong, L Feng, J Ensor, S K Wallace, S A Haque, G Rondon, K J Price, U Popat and J L Nates Bone Marrow Transplant 2015 50: 420-426; advance online publication, December 22, 2014; 10.1038/bmt.2014.287 Abstract | Full Text Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ≥60 B Federmann, C Faul, C Meisner, W Vogel, L Kanz and W A Bethge Bone Marrow Transplant 2015 50: 427-431; advance online publication, January 19, 2015; 10.1038/bmt.2014.292 Abstract | Full Text GRAFT-VERSUS-HOST DISEASE Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort Z Gul, E Van Meter, M Abidi, I Ditah, M Abdul-Hussein, A Deol, L Ayash, L G Lum, E K Waller, V Ratanatharathorn, J Uberti and Z Al-Kadhimi Bone Marrow Transplant 2015 50: 432-437; advance online publication, January 19, 2015; 10.1038/bmt.2014.284 Abstract | Full Text INFECTIONS Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT I Ceberio, K Dai, S M Devlin, J N Barker, H Castro-Malaspina, J D Goldberg, S Giralt, N G Adel and M-A Perales Bone Marrow Transplant 2015 50: 438-443; advance online publication, January 19, 2015; 10.1038/bmt.2014.286 Abstract | Full Text The association between donor and recipient statin use and infections after allogeneic hematopoietic cell transplantation S Seo, M Boeckh, B E Storer, M M Schubert, M Rotta, B M Sandmaier and M Mielcarek Bone Marrow Transplant 2015 50: 444-448; advance online publication, January 19, 2015; 10.1038/bmt.2014.279 Abstract | Full Text LETTERS TO THE EDITOR Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes B Dhakal, A Singavi, E P Cohen, M Dangal, J Palmer, A Dall, A D'Souza, M Hamadani and P N Hari Bone Marrow Transplant 2015 50: 449-451; advance online publication, November 10, 2014; 10.1038/bmt.2014.261 Full Text TLI-based reduced-intensity conditioning hematopoietic SCT for children and adolescents with high-risk nonmalignant disorders A A Hussein, A Al-Mousa, E Khattab, A Al-Zaben and H Frangoul Bone Marrow Transplant 2015 50: 452-454; advance online publication, November 24, 2014; 10.1038/bmt.2014.268 Full Text Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation G M T Guilcher, R Moorjani, T H Truong and V A Lewis Bone Marrow Transplant 2015 50: 455-456; advance online publication, December 8, 2014; 10.1038/bmt.2014.272 Full Text A prospective cohort study of the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT A K Kew, S Clarke, A Ridler, S Burrell, J-A Edwards, S Doucette and S Couban Bone Marrow Transplant 2015 50: 457-458; advance online publication, December 15, 2014; 10.1038/bmt.2014.273 Full Text Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation L Farnault, J Gertner-Dardenne, F Gondois-Rey, G Michel, H Chambost, I Hirsch and D Olive Bone Marrow Transplant 2015 50: 459-462; advance online publication, January 19, 2015; 10.1038/bmt.2014.275 Full Text Minimal antileukaemic treatment followed by reduced-intensity conditioning in three consecutive children with Fanconi anaemia and AML R Beier, B Maecker-Kolhoff, K-W Sykora, M Chao, C Kratz and M G Sauer Bone Marrow Transplant 2015 50: 463-464; advance online publication, December 22, 2014; 10.1038/bmt.2014.283 Full Text Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges J Zhang, M Mosunjac, A Moon, A Nooka and E K Waller Bone Marrow Transplant 2015 50: 465-468; advance online publication, January 12, 2015; 10.1038/bmt.2014.289 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com  More Nature Events